Solésence, Inc. has resolved a commercial disagreement with one of its customers through a structured settlement that both compensates the buyer and preserves a path toward future business. The company filed a Form 8-K on July 10, 2026, reporting that its wholly owned subsidiary, Solésence, LLC, entered into a Settlement Agreement and Release with Refy Beauty Ltd on July 6.
The agreement settles disputes related to certain consumer care products that Solésence previously sold to Refy. While the filing does not detail the nature of the product issues, the financial terms are straightforward. Solésence will pay Refy the British Pound Sterling equivalent of $938,000, spread across twelve equal monthly installments of $78,166.66. The first payment is due on August 5, 2026, with subsequent payments following every 30 days.
A settlement with a commercial off-ramp
The agreement includes a provision that could reduce the cash impact on Solésence if the two companies resume their commercial relationship. The parties agreed to a six-month exclusivity period during which they will work on developing a new SPF product. Should those efforts lead to a new supply agreement, the final six scheduled installment payments would be converted into credits toward Refy’s purchase of the SPF product under that new contract. This structure gives both sides an incentive to collaborate again, turning what could have been a purely adversarial resolution into a potential commercial restart.
The settlement agreement was filed as an exhibit to the 8-K, though certain confidential portions have been redacted. The disclosure was made under Item 1.01 of Form 8-K, which covers entry into material definitive agreements, signaling that the company views the settlement as significant enough to warrant prompt public disclosure.
Solésence, headquartered in Romeoville, Illinois, develops and manufactures skincare and beauty products, often partnering with brands to bring formulations to market. The dispute with Refy Beauty and its resolution illustrate the operational risks inherent in contract manufacturing relationships, where product quality or specification disagreements can lead to financial liabilities. The settlement amount, while not trivial for a company of Solésence’s size, is structured over a full year, which may limit the immediate strain on liquidity. The potential to offset half of the payments through a renewed supply relationship adds a layer of commercial pragmatism to the resolution.